Free Trial
NASDAQ:IMNM

Immunome Q1 2024 Earnings Report

Immunome logo
$7.63 -0.87 (-10.24%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$7.66 +0.03 (+0.34%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.46
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
$4.00 million
Beat/Miss
Missed by -$2.97 million
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunome's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunome Earnings Headlines

Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33
The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Immunome initiated with a Buy at Lake Street
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat